155 related articles for article (PubMed ID: 36340078)
1. Methyl Effect on the Metabolism, Chemical Stability, and Permeability Profile of Bioactive
Guedes JS; Carneiro TR; Pinheiro PSM; Fraga CAM; Sant Anna CMR; Barreiro EJ; Lima LM
ACS Omega; 2022 Nov; 7(43):38752-38765. PubMed ID: 36340078
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic and Antiproliferative Activity of LASSBio-2208 and the Attempts to Determine Its Drug Metabolism and Pharmacokinetics In Vitro Profile.
Pillpe-Meza RM; Gouveia WL; Barbosa G; Fraga CAM; Barreiro EJ; Lima LM
Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543175
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Effects of Anti-Inflammatory
Cordeiro N; Freitas RHCN; Fraga CAM; Fernandes PD
J Pharmacol Exp Ther; 2020 Sep; 374(3):420-427. PubMed ID: 32546529
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Profile Evaluation of Novel Combretastatin Derivative, LASSBio-1920, as a Promising Colorectal Anticancer Agent.
Guimarães CJ; Carneiro TR; Frederico MJS; de Carvalho GGC; Little M; Freire VN; França VLB; do Amaral DN; Guedes JS; Barreiro EJ; Lima LM; Barros-Nepomuceno FWA; Pessoa C
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111767
[TBL] [Abstract][Full Text] [Related]
5. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
Brito FC; Kummerle AE; Lugnier C; Fraga CA; Barreiro EJ; Miranda AL
Eur J Pharmacol; 2010 Jul; 638(1-3):5-12. PubMed ID: 20412790
[TBL] [Abstract][Full Text] [Related]
6. LASSBio-1586, an N-acylhydrazone derivative, attenuates nociceptive behavior and the inflammatory response in mice.
Silva JC; Oliveira Júnior RG; Silva MGE; Lavor ÉM; Soares JMD; Lima-Saraiva SRG; Diniz TC; Mendes RL; Alencar Filho EB; Barreiro EJL; Lima LM; Almeida JRGDS
PLoS One; 2018; 13(7):e0199009. PubMed ID: 30059558
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, solubility, plasma stability, and pharmacological evaluation of novel sulfonylhydrazones designed as anti-diabetic agents.
Zapata-Sudo G; da Costa Nunes IK; Araujo JS; da Silva JS; Trachez MM; da Silva TF; da Costa FP; Sudo RT; Barreiro EJ; Lima LM
Drug Des Devel Ther; 2016; 10():2869-2879. PubMed ID: 27672310
[TBL] [Abstract][Full Text] [Related]
8. In vitro microsomal hepatic metabolism of antiasthmatic prototype LASSBio-448.
Costa Nunes IK; Tinoco LW; Martins-Junior H; Rezende C; Barreiro EJ; Lima LM
Curr Top Med Chem; 2014; 14(11):1388-98. PubMed ID: 24805061
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical evaluation of LASSBio-1491: From in vitro pharmacokinetic study to in vivo leishmanicidal activity.
de Queiroz AC; Barbosa G; de Oliveira VRT; de Mattos Alves H; Alves MA; Carregaro V; Santana da Silva J; Barreiro EJ; Alexandre-Moreira MS; Lima LM
PLoS One; 2022; 17(6):e0269447. PubMed ID: 35666748
[TBL] [Abstract][Full Text] [Related]
10. Antinociceptive profile of 2,3,6-trisubstituted piperidine alkaloids: 3-O-acetyl-spectaline and semi-synthetic derivatives of (-)-spectaline.
Viegas C; Alexandre-Moreira MS; Fraga CA; Barreiro EJ; Bolzani Vda S; de Miranda AL
Chem Pharm Bull (Tokyo); 2008 Apr; 56(4):407-12. PubMed ID: 18379082
[TBL] [Abstract][Full Text] [Related]
11. LASSBio-1422: a new molecular scaffold with efficacy in animal models of schizophrenia and disorders of attention and cognition.
Betti AH; Antonio CB; Pompeu TE; Martins TS; Herzfeldt V; Stolz ED; Fraga CA; Barreiro E; Noël F; Rates SM
Behav Pharmacol; 2017 Feb; 28(1):48-62. PubMed ID: 27755061
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype.
Conrado DJ; Verli H; Neves G; Fraga CA; Barreiro EJ; Rates SM; Dalla Costa T
J Pharm Pharmacol; 2008 Jun; 60(6):699-707. PubMed ID: 18498705
[TBL] [Abstract][Full Text] [Related]
13. New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia.
Neves G; Antonio CB; Betti AH; Pranke MA; Fraga CA; Barreiro EJ; Noël F; Rates SM
Behav Brain Res; 2013 Jan; 237():86-95. PubMed ID: 23000351
[TBL] [Abstract][Full Text] [Related]
14. CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes and human recombinant CYP enzymes.
Fraga AG; da Silva LL; Fraga CA; Barreiro EJ
Eur J Med Chem; 2011 Jan; 46(1):349-55. PubMed ID: 21144625
[TBL] [Abstract][Full Text] [Related]
15. Vasodilator and antihypertensive effects of a novel N-acylhydrazone derivative mediated by the inhibition of L-type Ca²⁺ channels.
Pereira SL; Kummerle AE; Fraga CA; Barreiro EJ; Sudo RT; Zapata-Sudo G
Fundam Clin Pharmacol; 2014 Feb; 28(1):29-41. PubMed ID: 22958093
[TBL] [Abstract][Full Text] [Related]
16. Vasodilatory activity and antihypertensive profile mediated by inhibition of phosphodiesterase type 1 induced by a novel sulfonamide compound.
Pontes LB; Antunes F; Sudo RT; Raimundo JM; Lima LM; Barreiro EJ; Zapata-Sudo G
Fundam Clin Pharmacol; 2012 Dec; 26(6):690-700. PubMed ID: 22066694
[TBL] [Abstract][Full Text] [Related]
17. Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581.
Neves G; Kliemann M; Betti AH; Conrado DJ; Tasso L; Fraga CA; Barreiro EJ; Teresa Dalla Costa ; Rates SM
Pharmacol Biochem Behav; 2008 Mar; 89(1):23-30. PubMed ID: 18082872
[TBL] [Abstract][Full Text] [Related]
18. LASSBio-897 Reduces Lung Injury Induced by Silica Particles in Mice: Potential Interaction with the A
Carvalho VF; Ferreira TPT; de Arantes ACS; Noël F; Tesch R; Sant'Anna CMR; Barreiro EJL; Fraga CAM; Rodrigues E Silva PM; Martins MA
Front Pharmacol; 2017; 8():778. PubMed ID: 29163164
[TBL] [Abstract][Full Text] [Related]
19. Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer.
Guerra FS; Rodrigues DA; Fraga CAM; Fernandes PD
Pharmaceuticals (Basel); 2021 Apr; 14(5):. PubMed ID: 33919077
[TBL] [Abstract][Full Text] [Related]
20. LASSBio-596 protects gastric mucosa against the development of ethanol-induced gastric lesions in mice.
Monteiro CES; Sousa JAO; Lima LM; Barreiro EJ; da Silva-Leite KES; de Carvalho CMM; Girão DKFB; Reis Barbosa AL; de Souza MHLP; Gomes Soares PM
Eur J Pharmacol; 2019 Nov; 863():172662. PubMed ID: 31539551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
